Cancer/immunological diseases program (Vividion Therapeutics/Roche)

N/A

Report date: 2025/01/26 17:26:11
NME

Base Information

Drug NameCancer/immunological diseases program (Vividion Therapeutics/Roche)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionImmunomodulators
TargetsUpdating
Therapy Area/IndicationsImmune System DiseasesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVividion Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesRoche Holding LtdVividion Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsImmune System DiseasesNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A